Home » Stocks » SWTX

Springworks Therapeutics, Inc. (SWTX)

Stock Price: $82.99 USD 1.00 (1.22%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 4.07B
Revenue (ttm) 35.00M
Net Income (ttm) -60.07M
Shares Out 49.06M
EPS (ttm) -1.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $82.99
Previous Close $81.99
Change ($) 1.00
Change (%) 1.22%
Day's Open 82.82
Day's Range 79.61 - 83.76
Day's Volume 181,691
52-Week Range 35.20 - 96.48

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

STAMFORD, Conn., July 20, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,...

4 days ago - GlobeNewsWire

Pharma stocks like MNMD stock and ANVS stock offer investors long-term growth potential in a market on track to hit a value of $1.70 trillion. The post 7 Top-Rated Pharmaceutical Companies to Invest In ...

Other stocks mentioned: ANVS, BTX, CTXR, JAZZ, MNMD, SAVA
2 weeks ago - InvestorPlace

Precision BioSciences Inc (NASDAQ: DTIL) and SpringWorks Therapeutics Inc (NASDAQ: SWTX) have dosed the first patient in the combination arm of Precision's Phase 1/2a trial evaluating PBCAR269A.  In the...

Other stocks mentioned: DTIL
3 weeks ago - Benzinga

DURHAM, N.C. & STAMFORD, Conn.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with...

Other stocks mentioned: DTIL
3 weeks ago - Business Wire

SpringWorks Therapeutics Inc (NASDAQ: SWTX) announced an update on the previously reported interim data from the first 20 adult patients enrolled in Phase 2b ReNeu trial evaluating mirdametinib for NF1-...

1 month ago - Benzinga

STAMFORD, Conn., June 16, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients wi...

1 month ago - GlobeNewsWire

Additional Follow-up of First 20 Adult Patients Enrolled Continues to Show Encouraging Efficacy and Tolerability of Mirdametinib in Patients with NF1-PN Additional Follow-up of First 20 Adult Patients E...

1 month ago - GlobeNewsWire

AREC, RNLSY, and SWTX have been added to the Zacks Rank #5 (Strong Sell) List on June 10, 2021.

Other stocks mentioned: AREC, RNLSY
1 month ago - Zacks Investment Research

Continued Execution on Strategy to Advance Nirogacestat as a BCMA Potentiator Across Modalities Continued Execution on Strategy to Advance Nirogacestat as a BCMA Potentiator Across Modalities

1 month ago - GlobeNewsWire

STAMFORD, Conn., June 01, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients wi...

1 month ago - GlobeNewsWire

STAMFORD, Conn., May 14, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients wit...

2 months ago - GlobeNewsWire

As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first on ...

Other stocks mentioned: ALLK, HZNP, IBRX, IMAB, MNMD, SAGE
2 months ago - InvestorPlace

STAMFORD, Conn., May 10, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients wit...

2 months ago - GlobeNewsWire

SpringWorks Therapeutics Inc (NASDAQ: SWTX) has entered into an exclusive worldwide license agreement with Katholieke Universiteit Leuven (KU Leuven) and the Flanders Institute for Biotechnology (VIB) f...

2 months ago - Benzinga

– Reported Interim Data from Phase 2b ReNeu Trial of Mirdametinib in NF1-PN Demonstrating Encouraging Clinical Activity and Tolerability in the First 20 Adult Patients Enrolled –

2 months ago - GlobeNewsWire

- TEAD Inhibition Represents an Emerging Approach for Addressing Multiple Biomarker-Defined Cancers Characterized by Aberrant Hippo Pathway Signaling, which is Genetically Altered in up to 10% of Cancers -

2 months ago - GlobeNewsWire

SpringWorks (SWTX) doses the first patient in a phase Ib study evaluating nirogacestat in combination with teclistamab for the treatment of relapsed or refractory multiple myeloma.

3 months ago - Zacks Investment Research

SpringWorks Therapeutics Inc (NASDAQ: SWTX) has dosed the first patient in a Phase 1b clinical trial evaluating nirogacestat combined with Johnson & Johnson's (NYSE: JNJ)Janssen's teclistamab in patient...

3 months ago - Benzinga

STAMFORD, Conn., April 01, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients w...

3 months ago - GlobeNewsWire

STAMFORD, Conn., March 22, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients w...

4 months ago - GlobeNewsWire

SpringWorks Therapeutics Inc (NASDAQ: SWTX) reports interim data from the first 20 adult patients in its ongoing Phase 2b ReNeu trial evaluating mirdametinib for NF1-associated plexiform neurofibromas (...

4 months ago - Benzinga

- Reported Interim Data from Phase 2b ReNeu Trial of Mirdametinib in NF1-PN Demonstrating Encouraging Clinical Activity and Tolerability in the First 20 Adult Patients Enrolled - -  Allogene- and Jansse...

4 months ago - GlobeNewsWire

- Interim Data Reported from First 20 Adult Patients Enrolled with January 22, 2021 Data Cutoff -

4 months ago - GlobeNewsWire

STAMFORD, Conn., Feb. 22, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients wi...

5 months ago - GlobeNewsWire

STAMFORD, Conn., Feb. 04, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients wi...

5 months ago - GlobeNewsWire

Among the public companies that made the BioSpace list of the top up and coming life sciences firms in 2019 and 2020, the majority have seen gains in their share prices. Given this metric, investors mig...

Other stocks mentioned: BEAM, CRSP, EDIT, NTLA
6 months ago - GuruFocus

STAMFORD, Conn., Jan. 05, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients wi...

6 months ago - GlobeNewsWire

STAMFORD, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients wi...

7 months ago - GlobeNewsWire

STAMFORD, Conn., Nov. 24, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients wi...

8 months ago - GlobeNewsWire

- Enrollment Complete in the Phase 3 DeFi Trial of Nirogacestat in Adult Patients with Desmoid Tumors -

8 months ago - GlobeNewsWire

DUBLIN and STAMFORD, Conn., Oct. 26, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) ("SpringWorks") today announced that Jazz Pharmaceutic...

Other stocks mentioned: JAZZ
8 months ago - PRNewsWire

STAMFORD, Conn., Oct. 13, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients wi...

9 months ago - GlobeNewsWire

SpringWorks Therapeutics (SWTX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

STAMFORD, Conn., Oct. 07, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients wi...

9 months ago - GlobeNewsWire

STAMFORD, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients wi...

9 months ago - GlobeNewsWire

Fifth industry collaboration to evaluate nirogacestat as a BCMA potentiator across modalities Fifth industry collaboration to evaluate nirogacestat as a BCMA potentiator across modalities

9 months ago - GlobeNewsWire

STAMFORD, Conn., Sept. 22, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients...

10 months ago - GlobeNewsWire

STAMFORD, Conn., Sept. 18, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients...

10 months ago - GlobeNewsWire

Third collaboration to evaluate nirogacestat in combination with BCMA therapies across modalities Third collaboration to evaluate nirogacestat in combination with BCMA therapies across modalities

10 months ago - GlobeNewsWire

– Enrollment Complete in the Phase 3 DeFi Trial of Nirogacestat in Adult Patients with Desmoid Tumors - 

11 months ago - GlobeNewsWire

STAMFORD, Conn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...

11 months ago - GlobeNewsWire

STAMFORD, Conn., July 22, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...

1 year ago - GlobeNewsWire

Preclinical data presented at the American Association for Cancer Research 2020 Virtual Annual Meeting II

1 year ago - GlobeNewsWire

STAMFORD, Conn., June 22, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...

1 year ago - GlobeNewsWire

SpringWorks Therapeutics (SWTX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

STAMFORD, Conn., June 02, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...

1 year ago - GlobeNewsWire

STAMFORD, Conn., May 26, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients w...

1 year ago - GlobeNewsWire

- Announced Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039 - 

1 year ago - GlobeNewsWire

SpringWorks Therapeutics: View Ahead Of 2020 Catalysts

1 year ago - Seeking Alpha

STAMFORD, Conn., March 18, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. ...

1 year ago - GlobeNewsWire

About SWTX

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab ma... [Read more...]

Industry
Biotechnology
IPO Date
Sep 13, 2019
Stock Exchange
NASDAQ
Ticker Symbol
SWTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for SWTX stock is "Buy." The 12-month stock price forecast is 110.00, which is an increase of 32.55% from the latest price.

Price Target
$110.00
(32.55% upside)
Analyst Consensus: Buy